Nerac

Information That Drives Innovation

We’re here to help with your research needs
+1 860 872 7000
Customer Access
  • Home
  • What We Do
    • Nerac IPDex™
    • Innovation Insights and Consulting Practice
    • Regulatory
    • Medical Device and Life Sciences
    • Technology Scouting and Innovation
    • Market Research
    • Intellectual Property
    • Commercialization Services for TTOs and Start-Ups
    • Critical Updates
  • Who We Serve
  • How to Engage
  • Why Nerac?
  • Meet our Team
    • Leadership Team
    • Our Analysts
    • Our Partners
  • Nerac Insights and Publications
    • Articles
    • Case Studies
    • Press Room
    • Videos
    • Webcasts
    • White Papers
  • Contact Us
You are here: Home / Nerac Insights / Articles / FDA’s Proposed Regulatory Changes to Laboratory-Developed Tests (LDTs)

FDA’s Proposed Regulatory Changes to Laboratory-Developed Tests (LDTs)

Facebook0
Google+0
LinkedIn15
Twitter0

By Roz Sweeney, Ph.D., Nerac Analyst

Originally Published: November 17th, 2014

Introduction

The FDA recently issued updated draft guidance for proposed regulatory changes affecting laboratory developed tests (LDTs). Laboratory developed tests (or LDTs) are traditionally IVDs developed and used by CLIA labs for treating or testing patients within that lab’s associated healthcare facility. They have historically fallen under FDA enforcement discretion, under the rationale that they fall within the practice of medicine, which is not regulated by the FDA. (While the specific tests are exempt, the labs are regulated under the Clinical Laboratory Improvements Amendment of 1988.)

Over the past 30-40 years, LDT’s have evolved considerably as medicine has gotten more complex. The FDA believes that the claims of certain LDTs are not adequately supported with evidence and that certain LDTs may lack appropriate controls yielding erroneous results. The FDA is aware of harm caused by faulty LDTs. For example, the Agency is aware of harm caused by biomarker tests for early detection of ovarian cancer. In this case, patients received inappropriate treatments or even harmful treatments as a result of these tests.

Other reasons for the need for increased oversight include LDT’s being used on larger populations (e.g. outside of the local healthcare facility) and in situations where more stringently regulated devices exist (e.g. same indication and use as PMA approved devices). The proposed regulations are intended to even the playing field in safety, efficacy, and performance of LDT’s with class I, II, III IVDs.

Want to read the rest of the article? Fill out the form to download: FDA’s Proposed Regulatory Changes to Laboratory-Developed Tests (LDTs)
Get Download Link

 

 

 

 

Related Posts

  • Laboratory-Developed Test Regulations
    54
    By Roz Sweeney, Ph.D., Nerac Analyst Originally Published: September 19th, 2014 Will Laboratory-developed tests (LDTs) require FDA marketing approval? Laboratory-developed tests (LDTs) are in vitro diagnostic tests typically used within a single-institution’s CLIA lab. The FDA exempted clinical laboratories from registration and listing of tests almost 40 years ago; however, this exemption may no longer…
    Tags: tests, ldts, fda
  • Bringing Functional Foods to Market: FDA’s Regulatory Mandate Drives the Process
    50
    Originally published February, 2011 Introduction Bringing a new functional food product to market is a potentially complex process with many decision points driven by the US Food and Drug Administration’s (FDA) regulatory mandate. There is no single definition for functional foods, also known as nutraceuticals. They may encompass a range of products and uses, including…
    Tags: regulatory, fda, read, published, originally
  • Pharmacovigilance: Staying Compliant is Critical
    42
    By Joanne Ferrell and John Leavitt, Ph.D. Originally published October, 2013 Pharmacovigilance: What is it and why is it important? The requirements regarding post-market safety monitoring are more stringent now than ever. Numerous incidents involving marketed pharmaceuticals and over-the-counter (OTC) medicines in recent years have brought the issues of safety monitoring and risk management to…
    Tags: read, regulatory, clinical, originally, published, ph.d, fda
  • Case Studies
  • White Papers
  • Webcasts
  • Articles
    • Nerac Strategist
    • Energy
    • Food & Nutrition
    • Intellectual Property
    • Regulatory
    • Technology & Innovation
    • Medical Device & Healthcare
    • Pharmaceutical
    • Engineering
    • Market Research
    • Critical Alerts
    • Chemistry/Advanced Materials
  • Press Room

Click here to learn more about….

3d printing advanced materials aerospace Ask Kevin Videos biotech CFDA clinical literature evaluations commercialization strategies competitive intelligence conflict minerals Disruptive Technologies energy EU MDR FDA food helga weires Industry 4.0 innovation Inspiring Next intellectual property IP market analysis market research medical device medical devices nerac Nerac client questions Nerac Strategist notified body audit open innovation patenting patenting strategies patent landscape pharmaceutical Post-Market Surveillance R&D regulatory regulatory compliance Robert Beinstein Rosemarie Szostak specialty chemicals Sustainable Development Goals technology scouting Tech Scouting XcellR8
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube
  • Career Opportunities
  • Privacy Policy

Copyright © 2023 Nerac · One Technology Drive · Tolland, CT 06084 · 1.860.872.7000

Sign Up for the Nerac Strategist

Like what you see? Sign up here to receive the Nerac Strategist newsletter, a compilation of analyst insights on rapidly developing industry issues, compliance challenges and commercial opportunities!

  • This field is for validation purposes and should be left unchanged.